glp-1 mash therapies: a new frontier in treatment Incretin-based therapies in MASLD/MASH: from
Description
GLP-1 receptor agonists function by: Stimulating insulin release when blood sugar levels are high Reducing glucagon secretion, which helps lower blood sugar Slowing gastric emptying, leading to increased satiety Affecting appetite centers in the brain, reducing food intake While these mechanisms contribute to the drugs effectiveness, they may also play a role in potential side effects, including the rare but serious risk of NAION

Robust physical activity: 30 minutes of moderate- to high-intensity exercise, four to five days a week

Interest in diet/meal programs, diet and fitness apps, supplements/herbs, and elective surgery has also increased since last year, representing an ever-diversifying landscape of weight-loss solutions

While gradual dose titration is common, using GLP-1s at micro-doses specifically for menopause is currently unapproved and the long-term risks are unknown

Not logging your rotation

Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
